These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 33093531

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Analysis of Circulating microRNA Signatures and Preeclampsia Development.
    Martinez-Fierro ML, Garza-Veloz I.
    Cells; 2021 Apr 24; 10(5):. PubMed ID: 33923172
    [Abstract] [Full Text] [Related]

  • 4. Altered Maternal Plasma Glycogen Phosphorylase Isoenzyme BB as a Biomarker for Preeclampsia and Small for Gestational Age.
    McCarthy FP, Doyle A, Khashan AS, Kenny LC.
    Reprod Sci; 2016 Jun 24; 23(6):738-47. PubMed ID: 26614266
    [Abstract] [Full Text] [Related]

  • 5. Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin.
    Whigham CA, MacDonald TM, Walker SP, Pritchard N, Hannan NJ, Cannon P, Nguyen TV, Hastie R, Tong S, Kaitu'u-Lino TJ.
    Sci Rep; 2019 Jan 18; 9(1):235. PubMed ID: 30659233
    [Abstract] [Full Text] [Related]

  • 6. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia.
    Whigham CA, MacDonald TM, Walker SP, Pritchard N, Hannan NJ, Hastie R, Alwis N, Cannon P, Nguyen TV, Tong S, Kaitu'u-Lino T.
    Pregnancy Hypertens; 2019 Apr 18; 16():16-25. PubMed ID: 31056153
    [Abstract] [Full Text] [Related]

  • 7. Circulating Activin A is elevated at 36 weeks' gestation preceding a diagnosis of preeclampsia.
    Wong GP, Andres F, Walker SP, MacDonald TM, Cannon P, Nguyen TV, Keenan E, Hannan NJ, Tong S, Kaitu'u-Lino TJ.
    Pregnancy Hypertens; 2022 Mar 18; 27():23-26. PubMed ID: 34844073
    [Abstract] [Full Text] [Related]

  • 8. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR.
    Hromadnikova I, Kotlabova K, Ivankova K, Krofta L.
    PLoS One; 2017 Mar 18; 12(2):e0171756. PubMed ID: 28182660
    [Abstract] [Full Text] [Related]

  • 9. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume.
    Sonek J, Krantz D, Carmichael J, Downing C, Jessup K, Haidar Z, Ho S, Hallahan T, Kliman HJ, McKenna D.
    Am J Obstet Gynecol; 2018 Jan 18; 218(1):126.e1-126.e13. PubMed ID: 29097177
    [Abstract] [Full Text] [Related]

  • 10. Two-stage screening for preterm preeclampsia at 11-13 weeks' gestation.
    Wright A, Wright D, Syngelaki A, Georgantis A, Nicolaides KH.
    Am J Obstet Gynecol; 2019 Feb 18; 220(2):197.e1-197.e11. PubMed ID: 30414394
    [Abstract] [Full Text] [Related]

  • 11. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study.
    Barton JR, Woelkers DA, Newman RB, Combs CA, How HY, Boggess KA, Martin JN, Kupfer K, Sibai BM, PETRA (Preeclampsia Triage by Rapid Assay) Trial.
    Am J Obstet Gynecol; 2020 Mar 18; 222(3):259.e1-259.e11. PubMed ID: 31518550
    [Abstract] [Full Text] [Related]

  • 12. Identifying late-onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks' gestation.
    Whitehead CL, McNamara H, Walker SP, Alexiadis M, Fuller PJ, Vickers DK, Hannan NJ, Hastie R, Tuohey L, Kaitu'u-Lino TJ, Tong S.
    Am J Obstet Gynecol; 2016 Apr 18; 214(4):521.e1-521.e8. PubMed ID: 26880734
    [Abstract] [Full Text] [Related]

  • 13. Early-onset preeclampsia, plasma microRNAs, and endothelial cell function.
    Lip SV, Boekschoten MV, Hooiveld GJ, van Pampus MG, Scherjon SA, Plösch T, Faas MM.
    Am J Obstet Gynecol; 2020 May 18; 222(5):497.e1-497.e12. PubMed ID: 31836544
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
    O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
    Am J Obstet Gynecol; 2016 Jan 18; 214(1):103.e1-103.e12. PubMed ID: 26297382
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
    Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
    Am J Obstet Gynecol; 2016 Jul 18; 215(1):87.e1-87.e17. PubMed ID: 26875953
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serum levels of miR-628-3p and miR-628-5p during the early pregnancy are increased in women who subsequently develop preeclampsia.
    Martinez-Fierro ML, Carrillo-Arriaga JG, Luevano M, Lugo-Trampe A, Delgado-Enciso I, Rodriguez-Sanchez IP, Garza-Veloz I.
    Pregnancy Hypertens; 2019 Apr 18; 16():120-125. PubMed ID: 31056146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.